Latest Commercial Readiness News

Optiscan Imaging has lodged a 510(k) submission for its InForm digital pathology device, moving the product from development into formal US regulatory assessment. FDA clearance is not assured, but a successful determination could open the door to commercial distribution in the company’s target market.

FortifAI has emerged from its first year as an AI infrastructure company with $20.4 million in cash, but a $29 million statutory loss and sharply lower gaming revenue. The company now needs to turn NOL8’s early testing and partnerships into commercial adoption before its cash-backed growth strategy faces a harder test.

FirstWave Cloud Technology has lodged a provisional patent for an AI-driven network monitoring system that promises automated, explainable root cause diagnosis, aiming to boost its fastest-growing revenue stream.

Paradigm Biopharmaceuticals has surpassed its Phase 3 enrolment target for Zilosul®, secured over A$21 million in capital, and pivots towards clinical evidence generation with major data readouts expected.

Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.

Nanosonics reported steady FY26 revenue growth driven by its trophon disinfection platform and advanced the CORIS System towards commercial launch, backed by a strong balance sheet and a new $40 million share buyback.

Viridis Mining and Minerals completes a Definitive Feasibility Study for its Colossus Rare Earth Project, confirming strong economics and project readiness, while securing $120 million in equity funding to advance into execution.

Podium Minerals has secured a $4 million underwritten share purchase plan to fund advancing metallurgical work and site rehabilitation at its Parks Reef PGM Project, following a significant step-change in concentrator performance.

Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.

Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial stays on track for November topline results, buoyed by strong open-label extension enrolment and aligned EMA-FDA regulatory advice. A new antidepressant study publication and fresh patents add momentum, supported by a $16.7 million cash runway to mid-2027.

Island Pharmaceuticals has marked a major step forward in its antiviral program with the start of GMP manufacturing for Galidesivir, expanded USAMRIID collaboration, and FDA orphan drug designation. Regulatory approvals for compassionate use in Uganda’s Ebola outbreak and a new dose optimisation study with Texas Biomed further de-risk the pathway to approval.

Metallium has validated its Flash Joule Heating technology through extensive testing and multi-reactor operation, advancing towards commercial e-waste processing at its Texas campus in H1 2027.